Coverage
-
April 26, 2013
Purdue Pharma LP and Actavis Inc. announced Friday that they've agreed to end a New York patent infringement suit seeking to block Actavis' generic version of abuse-deterrent formulations of Purdue's multibillion-dollar drug OxyContin.
1 other articles on this case.
View all »